This Article Full Text (PDF) All Versions of this Article: 1076029607304094v1 14/3/319    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Google Scholar Articles by de Larrañaga, G. Articles by Fainboim, H. PubMed PubMed Citation Articles by de Larrañaga, G. Articles by Fainboim, H. Social Bookmarking                   What's this?

Plasma Plasminogen Activator Inhibitor-1 Levels and Nonalcoholic Fatty Liver in Individuals With Features of Metabolic Syndrome

Hemostasis and Thrombosis Laboratory, gabriela{at}inkmedia.com.ar

Silvia Perés Wingeyer, PhD

Hemostasis and Thrombosis Laboratory

Mabel Graffigna, MD

Endocrinology Division, Durand Hospital

Susana Belli, MD

Endocrinology Division, Durand Hospital

Karla Bendezú, MD

Hepatology Unit, Hospital of Infectious Diseases F. J. Muñiz

Silvia Alvarez, MD

Pathology Division, Posadas Hospital, Buenos Aires, Argentina

Oscar Levalle, MD

Endocrinology Division, Durand Hospital

Hugo Fainboim, MD

Hepatology Unit, Hospital of Infectious Diseases F. J. Muñiz

Fatty liver represents the liver component of metabolic syndrome and may be involved in plasminogen activator inhibitor-1 (PAI-1) synthesis. We studied plasma PAI-1 levels and relationships with risk factors for metabolic syndrome, including fatty liver, in 170 patients. Liver ultrasound scan was performed on all patients, and a liver biopsy was performed on those patients with chronically elevated transaminase levels. Plasma PAI-1 levels correlated significantly (P < .05) with body mass index, degree of steatosis, insulin resistance, insulin level, waist circumference, triglycerides, and high-density lipoprotein (HDL) -cholesterol. However, only body mass index (β = .455) and HDL-cholesterol (β = .293) remained predictors of PAI-1 levels. Liver biopsy revealed a significant correlation (P < .05) between insulin resistance (r = 0.381) or insulin level (r = 0.519) and liver fibrosis. In patients presenting features of metabolic syndrome, plasma PAI-1 levels were mainly conditioned by the whole-body fat content.

Key Words: fatty liver • insulin resistance • liver fibrosis • metabolic syndrome • PAI-1

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?